tocilizumab,obinutuzumab,glofitamab
jw pharma,roche
['leusm', 'lymsm', 'glofitamab']
congress #17icml| presented the extended follow-up &amp; a landmark analysis of the phase 2 study of glofitamab in pts with r/r lbcl. the median time of study was 21.2 months. n=155, cr=40%, orr=52%, by irc. safety profile was manageable #lymsm #leusm 
A global education platform providing clinical updates on a range of lymphoma subtypes and chronic lymphocytic leukemia (#CLL) #lymsm